 | | Vol. 12.34 – 31 August, 2021 |
| |
|
|
| Scientists demonstrated that overwhelming mitochondrial fragmentation in mutant hematopoietic stem cells and progenitors triggered ineffective hematopoiesis in myelodysplastic syndromes.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Overexpression of the glutamate/aspartate transporter, Glast, or deletion of glutamic-oxaloacetic transaminase 1, Got1 each increased aspartate levels in HSCs/progenitor cells and increased the function of HSCs but not colony-forming progenitors.
[Cell Stem Cell] |
|
|
|
| Researchers investigated a straightforward approach based on erythrocyte binding to promote antigen-specific tolerance to both peptides and proteins, and showed that a fully D-chiral peptide library could be selected in vivo for the de novo discovery of a robust erythrocyte binder, which they attached to peptide and protein antigens.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators reported that the epigenetic factor, Ten-Eleven Translocation 3 (TET3) dioxygenase was overexpressed in acute myeloid leukemia (AML) patients and functionally validated human leukemic stem cells, and was required for leukemic growth by virtue of its regulation of glucose metabolism in AML cells.
[Leukemia] |
|
|
|
| The authors demonstrated that ex vivo culture of human adult human hematopoietic stem/progenitor cells with Delta-like ligand under low oxygen tension limited ER stress in long-term repopulating-HSCs and lineage-committed progenitors compared with normoxic cultures.
[Stem Cell Reports] |
|
|
|
| The ability of CCT245718 to overcome TKD-mediated resistance was evaluated in a cell line-based model of drug resistance to Fms-like tyrosine kinase 3 (FLT3) inhibitors.
[British Journal of Cancer] |
|
|
|
| Researchers demonstrated that transplanted Arhgef2−/− fetal liver and bone marrow cells yielded impaired hematopoietic recovery and a production deficit from long-term HSCs, phenotypes that were not the result of differences in numbers of transplanted HSCs, their cell cycle status, level of apoptosis, progenitor output, or homing ability.
[Blood Advances] |
|
|
|
| The expression of miR-548ac and TRIM28 and the targeting relationship were identified, and the results demonstrated that the expression of miR-548ac was upregulated in acute myeloid leukemia (AML) cell lines and AML cell-secreted extracellular vesicles compared with CD34+ HSCs.
[Cancer Gene Therapy] |
|
|
|
| Scientists investigated the regulatory effects of Reelin on multiple myeloma and its underlying pathogenic mechanisms. In vitro studies showed that Reelin depletion regulated osteolysis and osteogenesis balance, cell cycle, invasiveness, and apoptosis in SP2/0 cells.
[Cell Death Discovery] |
|
|
|
| Investigators showed that the long-noncoding RNA colorectal neoplasia differentially expressed (CRNDE) was overexpressed in both acute myeloid leukemia samples and cell lines. CRNDE silencing inhibited proliferation and increased apoptotic rate and cell cycle arrest of KG-1a cells.
[Scientific Reports] |
|
|
|
| | Scientists analyzed the effect of decitabine on T-cell subpopulations in immune thrombocytopenia in vitro and in vivo. They found that low-dose decitabine promoted the generation and differentiation of regulatory T cells and augmented their immunosuppressive function.
[Blood] |
|
|
|
| The average survival time was shorter in patients with JAK/STAT and PHF6 comutation than that in other patients, suggesting a potential role of PHF6 in leukemia progression.
[Leukemia] |
|
|
|
| Researchers conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20-positive, Philadelphia (Ph)-negative precursor B cell acute lymphoblastic leukemia.
[Blood Advances] |
|
|
|
|
| The authors give an overview on the myriad of functions performed by lysosomes and their importance in malignant disease and discuss their relevance in hematopoietic cells and different ways to potentially target them in acute myeloid leukemia.
[Leukemia] |
|
|
|
|
| Bio-Path Holdings, Inc. announced that the US FDA has reviewed and cleared the Investigational New Drug application for BP1002, the company’s second drug candidate, for an initial Phase I/Ib clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
[Bio-Path Holdings, Inc.] |
|
|
|
|
| October 19, 2021
London, England, United Kingdom |
|
|
|
|
|
| | Sidney Kimmel Cancer Center at Jefferson Health – Philadelphia, Pennsylvania, United States |
|
|
|
| | Indiana University – Indianapolis, Indiana, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Danaher – Toronto, Ontario, Canada |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
